The estimated Net Worth of Ronald W Barrett is at least $246 Тысяча dollars as of 4 December 2017. Ronald Barrett owns over 14,156 units of Concert Pharmaceuticals Inc stock worth over $118,486 and over the last 9 years he sold CNCE stock worth over $0. In addition, he makes $127,827 as Independent Director at Concert Pharmaceuticals Inc.
Ronald has made over 3 trades of the Concert Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 14,156 units of CNCE stock worth $51,669 on 4 December 2017.
The largest trade he's ever made was exercising 17,699 units of Concert Pharmaceuticals Inc stock on 9 November 2015 worth over $20,000. On average, Ronald trades about 4,955 units every 76 days since 2015. As of 4 December 2017 he still owns at least 14,156 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Ronald Barrett stock trades at the bottom of the page.
Dr. Ronald W. Barrett Ph.D. serves as Independent Director of the Company. Dr. Barrett has served as a member of our Board since December 2007. Dr. Barrett has served at the Chief Executive Officer and Chairman of the board of directors of Medikine, Inc., a biopharmaceutical company, since June 2017, and served as its Executive Chair from December 2016 to June 2017. Dr. Barrett was a founder of XenoPort, Inc., a biopharmaceutical company, and served as its Chief Executive Officer from 2001 to October 2015, its Chief Scientific Officer from 1999 to 2001 and as a member of its board of directors from 1999 to October 2015. Prior to XenoPort, Dr. Barrett held various positions at Affymax Research Institute, a drug discovery company now owned by GlaxoSmithKline plc, and Abbott Laboratories, a healthcare company. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in Pharmacology from Rutgers University. Barrett’s industry and board experience, including his experience as the chief executive officer of a publicly traded biopharmaceutical company, make him a key contributor to our Board.
As the Independent Director of Concert Pharmaceuticals Inc, the total compensation of Ronald Barrett at Concert Pharmaceuticals Inc is $127,827. There are 9 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of $2,772,350.
Ronald's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... и Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: